Saturday, December 8, 2012

Hindsight: PPARg and Adipose Tissue

Back in 2006 there was a tremendous interest in the biology of peroxisome proliferator-activated receptor gamma (PPARg).

Not only had this nuclear hormone receptor been well recognised as a key regulator of adipocyte differentiation, but the introduction of thiazolidinediones (“glitazones”) in diabetes treatment sparked a tremendous amount of work in this ligand.

In a paper I co-athored with my French colleague Bart Staels, published in the Journal of Clinical Endocrinology and Metabolism in 2006, we reviewed the literature on the role of PPARg in regulating lipid and glucose metabolism in adipose tissue.

Our review included all articles we could find on the role of PPARg in adipose tissue of healthy individuals and those with obesity, metabolic syndrome, or type 2 diabetes published between 1990 and 2006.

As we discuss in detail in the article, PPARg is highly expressed in adipose tissue, where its activation with thiazolidinediones alters fat topography and adipocyte phenotype and up-regulates genes involved in fatty acid metabolism and triglyceride storage.

In addition, PPARg activation is associated with potentially beneficial effects on the expression and secretion of a range of factors, including adiponectin, resistin, IL-6, TNFalpha, plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, and angiotensinogen, as well as a reduction in plasma nonesterified fatty acid supply.

This effects of PPARg-agonists also extends to macrophages, where they suppress production of inflammatory mediators.

Thus, we speculated that PPARg-activating ligands may have a role in preventing progression of insulin resistance to diabetes and endothelial dysfunction to atherosclerosis.

Since then the optimism about this class of medications has been tempered by the fact that larger clinical trials have raised concerns particularly about cardiovascular complications in patients with heart failure.

At the time, however, this state-of-the-art review received considerable attention with over 230 citations to date.

AMS
Edmonton, Alberta

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Leave a Comment

In The News

Diabetics in most need of bariatric surgery, university study finds

Oct. 18, 2013 – Ottawa Citizen: "Encouraging more men to consider bariatric surgery is also important, since it's the best treatment and can stop diabetic patients from needing insulin, said Dr. Arya Sharma, chair in obesity research and management at the University of Alberta." Read article

» More news articles...

Publications
  • No items
  • » Browse and download more journal publications...

    Watch Dr. Sharma in the News!

    Dr. Sharma - NEWS Videos

    Listen to Dr. Sharma!

    Dr. Sharma - on CBC.ca

    Watch Dr. Sharma on Listen Up


  • Subscribe via Email

    Enter your email address:

    Delivered by FeedBurner




  • Arya Mitra Sharma
  • Disclaimer

    Postings on this blog represent the personal views of Dr. Arya M. Sharma. They are not representative of or endorsed by Alberta Health Services or the Weight Wise Program.
  • Archives

     

  • RSS Weighty Matters

  • Click for related posts

  • Disclaimer

    Medical information and privacy
    Any medical discussion on this page is intended to be of a general nature only. This page is not designed to give specific medical advice. If you have a medical problem you should consult your own physician for advice specific to your own situation.


  • Meta

  • Obesity Links

  • If you have benefitted from the information on this site, please take a minute to donate to its maintenance.

  • Home | News | KOL | Media | Publications | Trainees | About
    Copyright 2008–2014 Dr. Arya Sharma, All rights reserved.
    Blog Widget by LinkWithin